Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2017

Open Access 01-03-2017 | NON-THEMATIC REVIEW

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Authors: Salvatore Galdy, Angela Lamarca, Mairéad G. McNamara, Richard A. Hubner, Chiara A. Cella, Nicola Fazio, Juan W. Valle

Published in: Cancer and Metastasis Reviews | Issue 1/2017

Login to get access

Abstract

Human epidermal growth factor receptor 2 (HER2) overexpression and amplification have been reported as predictive markers for HER2-targeted therapy in breast and gastric cancer, whereas human epidermal growth factor receptor 3 (HER3) is emerging as a potential resistance factor. The aim of this study was to perform a systematic review and meta-analysis of the HER2 and HER3 overexpression and amplification in biliary tract cancers (BTCs). An electronic search of MEDLINE, American Society of Clinical Oncology (ASCO), European Society of Medical Oncology Congress (ESMO), and American Association for Cancer Research (AACR) was performed to identify studies reporting HER2 and/or HER3 membrane protein expression by immunohistochemistry (IHC) and/or gene amplification by in situ hybridization (ISH) in BTCs. Studies were classified as “high quality” (HQ) if IHC overexpression was defined as presence of moderate/strong staining or “low quality” (LQ) where “any” expression was considered positive. Of 440 studies screened, 40 met the inclusion criteria. Globally, HER2 expression rate was 26.5 % (95 % CI 18.9–34.1 %). When HQ studies were analyzed (n = 27 studies), extrahepatic BTCs showed a higher HER2 overexpression rate compared to intrahepatic cholangiocarcinoma: 19.9 % (95 % CI 12.8–27.1 %) vs. 4.8 % (95 % CI 0–14.5 %), respectively, p value 0.0049. HER2 amplification rate was higher in patients selected by HER2 overexpression compared to “unselected” patients: 57.6 % (95 % CI 16.2–99 %) vs. 17.9 % (95 % CI 0.1–35.4 %), respectively, p value 0.0072. HER3 overexpression (4/4 HQ studies) and amplification rates were 27.9 % (95 % CI 9.7–46.1 %) and 26.5 % (one study), respectively. Up to 20 % of extrahepatic BTCs appear to be HER2 overexpressed; of these, close to 60 % appear to be HER2 amplified, while HER3 is overexpressed or amplified in about 25 % of patients. Clinical relevance for targeted therapy should be tested in prospective clinical trials.
Literature
1.
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., et al. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England Journal of Medicine, 362(14), 1273–1281.CrossRefPubMed
2.
Valle, J. W., Furuse, J., Jitlal, M., Beare, S., Mizuno, N., Wasan, H., et al. (2014). Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, 25(2), 391–398.CrossRef
3.
4.
Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., et al. (2015). Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The Lancet.Oncology, 16(8), 967–978.CrossRefPubMedPubMedCentral
5.
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344(11), 783–792.CrossRefPubMed
6.
Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England), 376(9742), 687–697.CrossRef
7.
Law, L. Y. (2012). Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30(27), e271–e273.CrossRef
8.
9.
Subbiah, I. M., Subbiah, V., Tsimberidou, A. M., Naing, A., Kaseb, A. O., Javle, M., et al. (2013). Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget, 4(1), 153–162.PubMedCentral
10.
Javle, M., Churi, C., Kang, H. C., Shroff, R., Janku, F., Surapaneni, R., et al. (2015). HER2/neu-directed therapy for biliary tract cancer. Journal of Hematology & Oncology, 8, 58. doi:10.​1186/​s13045-015-0155-z.CrossRef
11.
Lee, J., Park, S. H., Chang, H. M., Kim, J. S., Choi, H. J., Lee, M. A., et al. (2012). Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. The Lancet.Oncology, 13(2), 181–188.CrossRefPubMed
12.
Chen, J. S., Hsu, C., Chiang, N. J., Tsai, C. S., Tsou, H. H., Huang, S. F., et al. (2015). A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, 26(5), 943–949.CrossRef
13.
Malka, D., Cervera, P., Foulon, S., Trarbach, T., de la Fouchardiere, C., Boucher, E., et al. (2014). Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. The Lancet.Oncology, 15(8), 819–828.CrossRefPubMed
14.
Leone, F., Marino, D., Cereda, S., Filippi, R., Belli, C., Spadi, R., et al. (2016). Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (vecti-BIL study). Cancer, 122(4), 574–581.CrossRefPubMed
15.
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., et al. (2007). ErbB receptors: from oncogenes to targeted cancer therapies. The Journal of Clinical Investigation, 117(8), 2051–2058.CrossRefPubMedPubMedCentral
16.
Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., et al. (2003). The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Molecular Cell, 11(2), 495–505.CrossRefPubMed
17.
Hudis, C. A. (2007). Trastuzumab—mechanism of action and use in clinical practice. The New England Journal of Medicine, 357(1), 39–51.CrossRefPubMed
18.
Hynes, N. E., & Lane, H. A. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer, 5(5), 341–354.CrossRefPubMed
19.
Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. The EMBO Journal, 16(7), 1647–1655.CrossRefPubMedPubMedCentral
20.
Baselga, J., & Swain, S. M. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 9(7), 463–475.CrossRefPubMed
21.
Sierke, S. L., Cheng, K., Kim, H. H., & Koland, J. G. (1997). Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. The Biochemical Journal, 322(Pt 3), 757–763.CrossRefPubMedPubMedCentral
22.
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., et al. (1996). A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Molecular and Cellular Biology, 16(10), 5276–5287.CrossRefPubMedPubMedCentral
23.
Amin, D. N., Sergina, N., Ahuja, D., McMahon, M., Blair, J. A., Wang, D., et al. (2010). Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Science Translational Medicine, 2(16), 16ra7.CrossRefPubMedPubMedCentral
24.
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York, N.Y.), 316(5827), 1039–1043.CrossRef
25.
Choi, B. K., Fan, X., Deng, H., Zhang, N., & An, Z. (2012). ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells. Cancer Medicine, 1(1), 28–38.CrossRefPubMedPubMedCentral
26.
Wolff, A. C., Hammond, M. E., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., et al. (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31(31), 3997–4013.CrossRef
27.
Hofmann, M., Stoss, O., Shi, D., Buttner, R., van de Vijver, M., Kim, W., et al. (2008). Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 52(7), 797–805.CrossRefPubMed
28.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Medicine: A Peer-Reviewed, Independent, Open-Access Journal, 3(3), e123–e130.
29.
Voravud, N., Foster, C. S., Gilbertson, J. A., Sikora, K., & Waxman, J. (1989). Oncogene expression in cholangiocarcinoma and in normal hepatic development. Human Pathology, 20(12), 1163–1168.CrossRefPubMed
30.
Vaidya, P., Yosida, T., Sakakura, T., Yatani, R., Noguchi, T., & Kawarada, Y. (1996). Combined analysis of expression of c-erbB-2, ki-67 antigen, and tenascin provides a better prognostic indicator of carcinoma of the papilla of vater. Pancreas, 12(2), 196–201.CrossRefPubMed
31.
Kamel, D., Paakko, P., Nuorva, K., Vahakangas, K., & Soini, Y. (1993). p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. The Journal of Pathology, 170(1), 67–72.CrossRefPubMed
32.
Yukawa, M., Fujimori, T., Hirayama, D., Idei, Y., Ajiki, T., Kawai, K., et al. (1993). Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis. Human Pathology, 24(1), 37–40.CrossRefPubMed
33.
Suzuki, H., Isaji, S., Pairojkul, C., & Uttaravichien, T. (2000). Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan. Journal of Hepato-Biliary-Pancreatic Surgery, 7(2), 206–211.CrossRefPubMed
34.
Aishima, S. I., Taguchi, K. I., Sugimachi, K., Shimada, M., Sugimachi, K., & Tsuneyoshi, M. (2002). c-erbB-2 and c-met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology, 40(3), 269–278.CrossRefPubMed
35.
Kalekou, H., & Miliaras, D. (2004). Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma. Journal of Gastroenterology and Hepatology, 19(7), 812–818.CrossRefPubMed
36.
Chaube, A., Tewari, M., Garbyal, R. S., Singh, U., & Shukla, H. S. (2006). Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in indian patients manuscript id: 8962091628764582. BMC Cancer, 6, 126.CrossRefPubMedPubMedCentral
37.
Zheng, J., & Zhu, Y. M. (2007). Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance. Hepatobiliary & Pancreatic Diseases International: HBPD INT, 6(4), 412–415.
38.
Schlitter, A. M., Jang, K. T., Kloppel, G., Saka, B., Hong, S. M., Choi, H., et al. (2015). Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 28(9), 1249–1264.CrossRef
39.
Ito, Y., Takeda, T., Sasaki, Y., Sakon, M., Yamada, T., Ishiguro, S., et al. (2001). Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathology, Research and Practice, 197(2), 95–100.CrossRefPubMed
40.
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., et al. (2012). Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology, 142(4), 1021–1031 e15.CrossRefPubMed
41.
Maurya, S. K., Tewari, M., Sharma, B., & Shukla, H. S. (2013). Expression of procaspase 3 and activated caspase 3 and its relevance in hormone-responsive gallbladder carcinoma chemotherapy. The Korean Journal of Internal Medicine, 28(5), 573–578.CrossRefPubMedPubMedCentral
42.
Suder, A., Ang, J. E., Kyle, F., Harris, D., Rudman, S., Kristeleit, R., et al. (2015). A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. European Journal of Cancer (Oxford, England: 1990), 51(16), 2275–2284.CrossRef
43.
Euscher, E. D., Marsh Jr., W. L., Lucas, J. G., & Frankel, W. L. (2007). Histologic and immunohistochemical changes in the stented common bile duct. Applied Immunohistochemistry & Molecular Morphology: AIMM / Official Publication of the Society for Applied Immunohistochemistry, 15(3), 299–304.CrossRef
44.
Zhu, L., Kim, K., Domenico, D. R., Appert, H. E., & Howard, J. M. (1996). Adenocarcinoma of duodenum and ampulla of vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA. Journal of Surgical Oncology, 61(2), 100–105.CrossRefPubMed
45.
Ooi, A., Suzuki, S., Nakazawa, K., Itakura, J., Imoto, I., Nakamura, H., et al. (2009). Gene amplification of myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma. Anticancer Research, 29(1), 19–26.PubMed
46.
Ajiki, T., Kamigaki, T., Hasegawa, Y., Fujino, Y., Suzuki, Y., Takeyama, Y., et al. (2001). Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater. Hepato-Gastroenterology, 48(41), 1266–1270.PubMed
47.
Brunt, E. M., & Swanson, P. E. (1992). Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver. American Journal of Clinical Pathology, 97(5 Suppl 1), S53–S61.PubMed
48.
Collier, J. D., Guo, K., Mathew, J., May, F. E., Bennett, M. K., Corbett, I. P., et al. (1992). c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. Journal of Hepatology, 14(2–3), 377–380.CrossRefPubMed
49.
Chow, N. H., Huang, S. M., Chan, S. H., Mo, L. R., Hwang, M. H., & Su, W. C. (1995). Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Research, 15(3), 1055–1059.PubMed
50.
Lei, S., Appert, H. E., Nakata, B., Domenico, D. R., Kim, K., & Howard, J. M. (1995). Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. International Journal of Pancreatology: Official Journal of the International Association of Pancreatology, 17(1), 15–21.
51.
Vaidya, P., Kawarada, Y., Higashiguchi, T., Yoshida, T., Sakakura, T., & Yatani, R. (1996). Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma. The Journal of Pathology, 178(2), 140–145.CrossRefPubMed
52.
Terada, T., Ashida, K., Endo, K., Horie, S., Maeta, H., Matsunaga, Y., et al. (1998). c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology, 33(4), 325–331.CrossRefPubMed
53.
Kim, Y. W., Huh, S. H., Park, Y. K., Yoon, T. Y., Lee, S. M., & Hong, S. H. (2001). Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncology Reports, 8(5), 1127–1132.PubMed
54.
Endo, K., Yoon, B. I., Pairojkul, C., Demetris, A. J., & Sirica, A. E. (2002). ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (Baltimore, Md.), 36(2), 439–450.CrossRef
55.
Ukita, Y., Kato, M., & Terada, T. (2002). Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. Journal of Hepatology, 36(6), 780–785.CrossRefPubMed
56.
Altimari, A., Fiorentino, M., Gabusi, E., Gruppioni, E., Corti, B., D'Errico, A., et al. (2003). Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 35(5), 332–338.CrossRef
57.
Matsuyama, S., Kitajima, Y., Sumi, K., Mori, D., Satoh, T., & Miyazaki, K. (2004). Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. Oncology Reports, 11(4), 815–819.PubMed
58.
Kim, H. J., Kim, J. S., Kang, C. D., Lee, S. J., Kim, J. Y., Yeon, J. E., et al. (2005). Expression of epidermal growth factor receptor, ErbB2 and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma. The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi, 45(1), 52–59.PubMed
59.
Nakazawa, K., Dobashi, Y., Suzuki, S., Fujii, H., Takeda, Y., & Ooi, A. (2005). Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. The Journal of Pathology, 206(3), 356–365.CrossRefPubMed
60.
Settakorn, J., Kaewpila, N., Burns, G. F., & Leong, A. S. (2005). FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. Journal of Clinical Pathology, 58(12), 1249–1254.CrossRefPubMedPubMedCentral
61.
Ogo, Y., Nio, Y., Yano, S., Toga, T., Koike, M., Hashimoto, K., et al. (2006). Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma. Anticancer Research, 26(1B), 763–770.PubMed
62.
Joo, H. H., Song, E. Y., Jin, S. H., Oh, S. H., & Choi, Y. K. (2007). Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers. The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi, 50(6), 370–378.PubMed
63.
Kawamoto, T., Krishnamurthy, S., Tarco, E., Trivedi, S., Wistuba, I. I., Li, D., et al. (2007). HER receptor family: novel candidate for targeted therapy for gallbladder and extrahepatic bile duct cancer. Gastrointestinal Cancer Research: GCR, 1(6), 221–227.PubMedPubMedCentral
64.
Kim, H. J., Yoo, T. W., Park, D. I., Park, J. H., Cho, Y. K., Sohn, C. I., et al. (2007). Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, 18(5), 892–897.CrossRef
65.
Puhalla, H., Wrba, F., Kandioler, D., Lehnert, M., Huynh, A., Gruenberger, T., et al. (2007). Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Research, 27(3B), 1679–1684.PubMed
66.
Baumhoer, D., Zlobec, I., Tornillo, L., Dietmaier, W., Wuensch, P. H., Hartmann, A., et al. (2008). Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater. Virchows Archiv: An International Journal of Pathology, 453(6), 579–588.CrossRef
67.
Kaufman, M., Mehrotra, B., Limaye, S., White, S., Fuchs, A., Lebowicz, Y., et al. (2008). EGFR expression in gallbladder carcinoma in North America. International Journal of Medical Sciences, 5(5), 285–291.CrossRefPubMedPubMedCentral
68.
Miyahara, N., Shoda, J., Ishige, K., Kawamoto, T., Ueda, T., Taki, R., et al. (2008). MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. European Journal of Cancer (Oxford, England: 1990), 44(7), 1048–1056.CrossRef
69.
Yoshikawa, D., Ojima, H., Iwasaki, M., Hiraoka, N., Kosuge, T., Kasai, S., et al. (2008). Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. British Journal of Cancer, 98(2), 418–425.CrossRefPubMed
70.
Aloysius, M. M., Lobo, D. N., Rowlands, B. J., Madhusudan, S., Ilyas, M., & Zaitoun, A. M. (2009). HER-2/neu overexpression is a rare event in peri-ampullary cancer: assessment using the HercepTest. Histopathology, 55(2), 236–237.CrossRefPubMed
71.
Choi, H. J., Kim, H. J., & Choi, J. H. (2009). Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma. Hepato-Gastroenterology, 56(91–92), 606–609.PubMed
72.
Harder, J., Waiz, O., Otto, F., Geissler, M., Olschewski, M., Weinhold, B., et al. (2009). EGFR and HER2 expression in advanced biliary tract cancer. World Journal of Gastroenterology, 15(36), 4511–4517.CrossRefPubMedPubMedCentral
73.
Pignochino, Y., Sarotto, I., Peraldo-Neia, C., Penachioni, J. Y., Cavalloni, G., Migliardi, G., et al. (2010). Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer, 10, 631. doi:10.​1186/​1471-2407-10-631.CrossRefPubMedPubMedCentral
74.
Shafizadeh, N., Grenert, J. P., Sahai, V., & Kakar, S. (2010). Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Human Pathology, 41(4), 485–492.CrossRefPubMed
75.
Kumari, N., Kapoor, V. K., Krishnani, N., Kumar, K., & Baitha, D. K. (2012). Role of C-erbB2 expression in gallbladder cancer. Indian Journal of Pathology & Microbiology, 55(1), 75–79.CrossRef
76.
Lee, H. J., Chung, J. Y., Hewitt, S. M., Yu, E., & Hong, S. M. (2012). HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. Virchows Archiv: An International Journal of Pathology, 461(5), 521–530.CrossRef
77.
Toledo, C., Matus, C. E., Barraza, X., Arroyo, P., Ehrenfeld, P., Figueroa, C. D., et al. (2012). Expression of HER2 and bradykinin B(1) receptors in precursor lesions of gallbladder carcinoma. World Journal of Gastroenterology, 18(11), 1208–1215.CrossRefPubMedPubMedCentral
78.
Graham, R. P., Barr Fritcher, E. G., Pestova, E., Schulz, J., Sitailo, L. A., Vasmatzis, G., et al. (2014). Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Human Pathology, 45(8), 1630–1638.CrossRefPubMed
79.
Roa, I., de Toro, G., Schalper, K., de Aretxabala, X., Churi, C., & Javle, M. (2014). Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointestinal Cancer Research: GCR, 7(2), 42–48.PubMedPubMedCentral
80.
Wang, W., Zhang, J., Zhan, X., Lin, T., Yang, M., Hu, J., et al. (2014). SOX4 is associated with poor prognosis in cholangiocarcinoma. Biochemical and Biophysical Research Communications, 452(3), 614–621.CrossRefPubMed
81.
Yang, X., Wang, W., Wang, C., Wang, L., Yang, M., Qi, M., et al. (2014). Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncology Reports, 32(2), 700–708.PubMed
82.
Hechtman, J. F., Liu, W., Sadowska, J., Zhen, L., Borsu, L., Arcila, M. E., et al. (2015). Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 28(8), 1123–1129.CrossRef
83.
Kawamoto, T., Ishige, K., Thomas, M., Yamashita-Kashima, Y., Shu, S., Ishikura, N., et al. (2015). Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. Journal of Gastroenterology, 50(4), 467–479.CrossRefPubMed
84.
Oliveira Fernandes, V.T., De Barros E, Silva, M.J., Begnami, M.D., Saito, A. (2015). Prognosis of HER2 expression in cholangiocarcinoma when evaluated using gastric cancer methodology of immunohistochemistry. Journal of Clinical Oncology, 33, 2015 (suppl; abstr e15203).
85.
Holcombe, R.F, Xiu, J., Pishvaian, M.J., Millis, S.Z., Gatalica, Z., Reddy, S.K., et al. (2015). Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets. Journal of Clinical Oncology,33, 2015 (suppl 3; abstr 285).
86.
Wiggers, J. K., Ruys, A. T., Groot Koerkamp, B., Beuers, U., ten Kate, F. J., & van Gulik, T. M. (2014). Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Journal of Gastroenterology and Hepatology, 29(8), 1582–1594.CrossRefPubMed
87.
Yoshida, H., Shimada, K., Kosuge, T., & Hiraoka, N. (2016). A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. Virchows Archiv: An International Journal of Pathology, 468(4), 431–439.CrossRef
88.
Kiguchi, K., Carbajal, S., Chan, K., Beltran, L., Ruffino, L., Shen, J., et al. (2001). Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Research, 61(19), 6971–6976.PubMed
89.
Wadhwa, R., Song, S., Lee, J. S., Yao, Y., Wei, Q., & Ajani, J. A. (2013). Gastric cancer-molecular and clinical dimensions. Nature Reviews Clinical Oncology, 10(11), 643–655.CrossRefPubMedPubMedCentral
90.
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., et al. (2015). Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 26(Suppl 5), v8–30.CrossRef
91.
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., Andre, F., et al. (2014). ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger. Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, 25(10), 1871–1888.CrossRef
92.
Press, M. F., Hung, G., Godolphin, W., & Slamon, D. J. (1994). Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Research, 54(10), 2771–2777.PubMed
93.
Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M., Lenz, H. J., Yen, Y., et al. (2009). A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemotherapy and Pharmacology, 64(4), 777–783.CrossRefPubMed
94.
Peck, J., Wei, L., Zalupski, M., O'Neil, B., Villalona Calero, M., & Bekaii-Saab, T. (2012). HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology, 82(3), 175–179.CrossRefPubMed
95.
Hecht, J. R., Bang, Y. J., Qin, S. K., Chung, H. C., Xu, J. M., Park, J. O., et al. (2016). Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34(5), 443–451.CrossRef
96.
Satoh, T., Xu, R. H., Chung, H. C., Sun, G. P., Doi, T., Xu, J. M., et al. (2014). Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 32(19), 2039–2049.CrossRef
Metadata
Title
HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Authors
Salvatore Galdy
Angela Lamarca
Mairéad G. McNamara
Richard A. Hubner
Chiara A. Cella
Nicola Fazio
Juan W. Valle
Publication date
01-03-2017
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2017
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-016-9645-x

Other articles of this Issue 1/2017

Cancer and Metastasis Reviews 1/2017 Go to the issue

Erratum

Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma

OriginalPaper

Metastatic melanoma: how research can modify the course of a disease

OriginalPaper

Identification, genetic testing, and management of hereditary melanoma

OriginalPaper

Precision medicine driven by cancer systems biology

OriginalPaper

Crosstalk signaling in targeted melanoma therapy

Clinical

Next generation predictive biomarkers for immune checkpoint inhibition
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits